TLSI Stock Analysis: Buy, Sell, or Hold?
TLSI - TriSalus Life Sciences, Inc. Common Stock
$5.27
0.04 (0.76%)
â˛
5d:
+0.0%
30d:
+23.42%
90d:
+52.75%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When TLSI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TLSI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TLSI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: TLSI is currently trading at $5.27, which is considered slightly high relative to its 30-day fair value range of $4.29 to $5.39.
Technical Outlook: Technically, TLSI is in a uptrend. The price is currently testing key support at $5.18. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TLSI scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+91.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TLSI is in a uptrend. The price is currently testing key support at $5.18. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TLSI scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+91.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$4.29 -
$5.39
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 91.2% below Wall St target ($10.00)
- WARNING: Composite score 35/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.29 -
$5.39
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$5.18
Resistance Level
$5.91
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.12
Wall Street Target
$10.00
(+91.2%)
Revenue Growth (YoY)
1.7%
Profit Margin
-62.6%
Share & Embed Analysis
Last updated: August 23, 2026 9:07 AM ET
Data refreshes hourly during market hours. Next update: 10:07 AM
Data refreshes hourly during market hours. Next update: 10:07 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLSI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Mary T Szela
SELL
15944 shares
2026-03-17
Bryan F Cox
SELL
579 shares
2026-03-16
Jodi Devlin
SELL
273 shares
2026-03-16
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 37 SELL |
